A bioassay of @entity2591 for possible carcinogenicity was conducted by administering the test chemical by intraperitoneal injection to @entity35 and B6C3F1 @entity19 . Groups of 35 @entity35 of each sex were administered @entity2591 at one of two doses, either 2.6 or 5.2 mg/kg body weight, in buffered saline three times per week for 34 weeks, and were then observed for 46 or 47 weeks. Controls consisted of groups of 15 @entity35 of each sex that received injections of buffered saline (vehicle controls) and 15 @entity35 of each sex that were untreated (untreated controls). All surviving @entity35 were killed at 80 or 81 weeks. Groups of 35 @entity19 of each sex were administered the chemical at one of two doses, either 2.2 or 4.4 mg/kg body weight, in buffered saline three times per week for 52 weeks, and were then observed for 29 or 30 weeks. Controls consisted of groups of 15 @entity19 of each sex that received injections of buffered saline (vehicle controls) and 15 @entity19 of each sex that were untreated (untreated controls). All surviving @entity19 were killed at 81 or 82 weeks. @entity2591 was toxic to the animals in this bioassay, since mean body weights of both treated @entity35 and treated @entity19 were lower than those of the corresponding vehicle controls, and since none of the high-dose male and female @entity35 and high-dose female @entity19 lived to the end of the bioassay. In treated male and female @entity35 and male @entity19 , survival was inadequate for meaningful statistical analyses of the incidences of @entity5 . Only one male and three female high-dose @entity35 had @entity5 ,and none of the @entity5 in the low-dose group of either sex were present at a significantly increased incidence using any of the statistical tests. Bone-marrow @entity194 was present in both treated groups of both sexes of @entity35 . Only five high-dose male @entity19 and one high-dose female @entity19 had @entity5 . In low-dose female @entity19 , however, lymphocytic and @entity8116 of the hematopoietic system occurred in 17 animals, even though only 54% survived until week 81. @entity8116 were observed in 10/29 low-dose female @entity19 , but in no other group, and were significant (P=0.010) compared with the vehicle controls. The incidence of @entity706 and @entity8116 was highly significant in the low-dose females (vehicle controls 0/14, low-dose 17/29, P<0.001). No @entity5 were observed at a significant incidence in male @entity19 . Bone-marrow @entity194 was present in high-dose female @entity19 . It is concluded that under the conditions of this bioassay, the short life span and short duration of treatment of @entity35 of either sex and of male B6C3F1 @entity19 precluded evaluation of the carcinogenicity of @entity2591 in these groups; however, the induction of @entity5 of the hematopoietic system in female B6C3F1 @entity19 was associated with the administration of @entity2591 .

Bioassay of XXXX for possible carcinogenicity.

@entity2591 :: ('MESH:D001374', 'Chemical') :: ['5-azacytidine', '5-Azacytidine'] @entity706 :: ('MESH:D008223', 'Disease') :: ['combined lymphoma'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity5 :: ('MESH:D009369', 'Disease') :: ['neoplasms', 'tumors'] @entity8116 :: ('MESH:D007960', 'Disease') :: ['Granulocytic neoplasms', 'granulocytic neoplasms'] @entity194 :: ('MESH:D001284', 'Disease') :: ['atrophy'] @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']
@entity2591 :: (MESH:D001374,Chemical) :: ['5-azacytidine']
